Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously presented) A composition comprising a compound of formula (I), or a solvate or pharmaceutically acceptable salt thereof:



(I)

wherein, independently at each occurrence,

n is selected from 1, 3 and 4;

Q is either O (oxygen) or –O-C(O)-;

X is selected from a direct bond, -C(R_6,R_{14})-Y-, and -C(R_{13})=CH-;

Y is selected from a direct bond, O, S, and C_1-C_4alkylene;

R_{13} is selected from hydrogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, aryl, and benzyl;

R_1 and R_2 are independently selected from C_3-C_8alkoxyalkyl, C_1-C_8hydroxyalkyl, and C_7-C_{12}aralkyl; or

R_1 and R_2, are taken together with the nitrogen atom to which they are directly attached in formula (I), to form a ring denoted by formula (II):



(II)

wherein the ring of formula (II) is formed from the nitrogen as shown as well as three to nine additional ring atoms independently selected from carbon, nitrogen, oxygen, and sulfur; where any two adjacent ring atoms may be joined together by single or double bonds, and where any one or more of the additional carbon ring atoms may be substituted with one or two substituents selected from hydrogen, hydroxy, C_1-C_3hydroxyalkyl, oxo, C_2-C_4acyl, C_1-C_3alkyl, C_2-C_4alkylcarboxy, C_1-C_3alkoxy, C_1-C_{20}alkanoyloxy, or may be substituted to form a spiro five- or six-membered heterocyclic ring containing one or two heteroatoms selected from oxygen and sulfur; and any two adjacent additional carbon ring atoms may be fused to a C_3-C_8carbocyclic ring, and any one or more of the additional nitrogen ring atoms may be substituted with substituents selected from hydrogen, C_1-C_6alkyl, C_2-C_4acyl, C_2-C_4hydroxyalkyl and C_3-C_8alkoxyalkyl; or

R_1 and R_2, are taken together with the nitrogen atom to which they are directly attached in formula (I), to form a bicyclic ring system selected from 3-azabicyclo[3.2.2]nonan-3-yl, 2-aza-bicyclo[2.2.2]octan-2-yl, 3-azabicyclo[3.1.0]-hexan-3-yl, and 3-azabicyclo[3.2.0]-heptan-3-yl;

R_3 and R_4 are independently attached to the cycloalkyl ring shown in formula (I) at other than the 1 and 2 positions and are independently selected from hydrogen, hydroxy, C_1-C_6alkyl, and C_1-C_6alkoxy, and, when both R_3 and R_4 are attached to the same cycloalkane ring atom, may together form a spiro five- or six-membered heterocyclic ring containing one or two heteroatoms selected from oxygen and sulfur;

R_5, R_6 and R_{14} are independently selected from hydrogen, C_1-C_6alkyl, aryl and benzyl, or R_6 and R_{14}, when taken together with the carbon to which they are attached, may form a spiro C_3-C_5cycloalkyl;

A is selected from C_5-C_{12}alkyl, a C_3-C_{13}carbocyclic ring, and ring systems selected from formulae (III), (IV), (V), (VI), (VII) and (VIII):



(III)

where R_7, R_8 and R_9 are independently selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl, C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl, aryl and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl;



and



(IV) (V)

where R_{10} and R_{11} are independently selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl, C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl, and $N(R_{15},R_{16})$ where R_{15} and R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl;



(VI)

where R_{12} is selected from bromine, chlorine, fluorine, carboxy, hydrogen, hydroxy, hydroxymethyl, methanesulfonamido, nitro, sulfamyl, trifluoromethyl, C_2-C_7alkanoyloxy, C_1-C_6alkyl, C_1-C_6alkoxy, C_2-C_7alkoxycarbonyl, C_1-C_6thioalkyl, and $N(R_{15},R_{16})$ where R_{15} and

R_{16} are independently selected from hydrogen, acetyl, methanesulfonyl, and C_1-C_6alkyl; and Z is selected from CH, CH_2, O, N and S, where Z may be directly bonded to "X" as shown in formula (I) when Z is CH or N, or Z may be directly bonded to R_{17} when Z is N, and R_{17} is selected from hydrogen, C_1-C_6alkyl, C_3-C_8cycloalkyl, aryl and benzyl;



(VII)



(VIII)

including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof.

2. (Previously presented) A composition comprising a compound selected from the group consisting of (1R,2R)-2- (4-Morpholinyl)-1-(2-naphthalenethoxy)cyclopentane; (1S,2S)-2-(4-Morpholinyl)-1-(2-naphthalenethoxy)cyclopentane; (1R,2R)-2-(3-Ketopyrrolidinyl)-1-(2,6-dichlorophenethoxy)cyclopentane; (1S, 2S)-2-(3-Ketopyrrolidinyl)-1-(2,6-dichlorophenethoxy)cyclopentane; and pharmaceutically acceptable salts and solvates of any of the foregoing; or

a mixture of compounds selected from the group consisting of a mixture of (1R,2R)-2-(4-Morpholinyl)-1-(2-naphthalenethoxy)cyclopentane and (1S,2S)-2-(4-Morpholinyl)-1-(2-naphthalenethoxy)cyclopentane, a mixture of (1R,2R)-2-(3-Ketopyrrolidinyl)-1-(2,6-dichlorophenethoxy)cyclopentane and (1S, 2S)-2-(3-Ketopyrrolidinyl)-1-(2,6-dichlorophenethoxy)cyclopentane; and a mixture of pharmaceutically acceptable salts and solvates of any of the foregoing.

3. (Previously presented) The composition of claim 1,

wherein R_1 and R_2, are taken together with the nitrogen atom to which they are directly attached in formula (I), to form a ring denoted by formula (II):



(II)

wherein the ring of formula (II) is formed from the nitrogen as shown as well as three to nine additional ring atoms independently selected from carbon, nitrogen, oxygen, and sulfur; where any two adjacent ring atoms may be joined together by single or double bonds, and where any one or more of the additional carbon ring atoms may be substituted with one or two substituents selected from hydrogen, hydroxy, C_1-C_3hydroxyalkyl, oxo, C_2-C_4acyl, C_1-C_3alkyl, C_2-C_4alkylcarboxy, C_1-C_3alkoxy, C_1-C_{20}alkanoyloxy, or may be substituted to form a spiro five- or six-membered heterocyclic ring containing one or two heteroatoms selected from oxygen and sulfur; and any two adjacent additional carbon ring atoms may be fused to a C_3-C_8carbocyclic ring, and any one or more of the additional nitrogen ring atoms may be substituted with substituents selected from hydrogen, C_1-C_6alkyl, C_2-C_4acyl, C_2-C_4hydroxyalkyl and C_3-C_8alkoxyalkyl; or

R_1 and R_2, are taken together with the nitrogen atom to which they are directly attached in formula (I), to form a bicyclic ring system selected from 3-azabicyclo[3.2.2]nonan-3-yl, 2-aza-bicyclo[2.2.2]octan-2-yl, 3-azabicyclo[3.1.0]-hexan-3-yl, and 3-azabicyclo[3.2.0]-heptan-3-yl.

4. (Canceled)

5. (Previously presented) A method for treating arrhythmia in a warm-blooded animal comprising administering to a warm-blooded animal in need of such treatment a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

6. (Previously presented) A method for modulating ion channel activity in a warm-blooded animal comprising administering to a warm-blooded animal in need of ion channel activity modulation a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

7. (Previously presented) A method for modulating ion channel activity in vitro comprising contacting an in vitro ion channel with a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

8. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat diseases of the central nervous system in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

9. (Previously presented) A method for treating diseases of the central nervous system in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

10. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat convulsion in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

11. (Previously presented) A method for treating convulsion in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

12. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat epileptic spasms in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

13. (Previously presented) A method for treating epileptic spasms in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

14. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat depression, anxiety or schizophrenia, in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

15. (Previously presented) A method for treating depression, anxiety or schizophrenia, in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

16. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat Parkinson's disease in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

17. (Previously presented) A method for treating Parkinson's disease in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

18. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat respiratory disorders in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

19. (Previously presented) A method for treating respiratory disorders in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

20. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat cystic fibrosis in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

21. (Previously presented) A method for treating cystic fibrosis in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

22. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat asthma in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

23. (Previously presented) A method for treating asthma in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

24. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat a cough in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

25. (Previously presented) A method for treating a cough in a warm-blooded animal comprising administration of a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

26. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat inflammation in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

27. (Previously presented) A method for treating inflammation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

28. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat arthritis in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

29. (Previously presented) A method for treating arthritis in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

30. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat allergies in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

31. (Previously presented) A method for treating allergies in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

32. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat gastrointestinal disorders in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

33. (Previously presented) A method for treating gastrointestinal disorders in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

34. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat urinary incontinence in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

35. (Previously presented) A method for treating urinary incontinence in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

36. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat irritable bowel syndrome in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

37. (Previously presented) A method for treating irritable bowel syndrome in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

38. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat cardiovascular diseases in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

39. (Previously presented) A method for treating cardiovascular diseases in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

40. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat cerebral or myocardial ischemias in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

41. (Previously presented) A method for treating cerebral or myocardial ischemias in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

42. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat hypertension in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

43. (Previously presented) A method for treating hypertension in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

44. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat long-QT syndrome in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

45. (Previously presented) A method for treating long-QT syndrome in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

46. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat stroke in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

47. (Previously presented) A method for treating stroke in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

48. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat migraine in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

49. (Previously presented) A method for treating migraine in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

50. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat ophthalmic diseases in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

51. (Previously presented) A method for treating ophthalmic diseases in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

52. (Previously presented) A pharmaceutical composition comprising an amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2 effective to treat diabetes mellitus in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

53. (Previously presented) A method for treating diabetes mellitus in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a composition according to claim 1 or 3 or a composition or mixture of compounds according to claim 2.

54. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat myopathies in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

55. (Previously presented) A method for treating myopathies in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

56. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat Becker's myotonia in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

57. (Previously presented) A method for treating Becker's myotonia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

58. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat myasthenia gravis in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

59. (Previously presented) A method for treating myasthenia gravis in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

60. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat paramyotonia congentia in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

61. (Previously presented) A method for treating paramyotonia congentia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

62. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat malignant hyperthermia in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

63. (Previously presented) A method for treating malignant hyperthermia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

64. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat hyperkalemic periodic paralysis in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

65. (Previously presented) A method for treating hyperkalemic periodic paralysis in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

66. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat Thomsen's myotonia in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

67. (Previously presented) A method for treating Thomsen's myotonia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

68. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat autoimmune disorders in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

69. (Previously presented) A method for treating autoimmune disorders in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

70. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat graft rejection in organ transplantation or bone marrow transplantation in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

71. (Previously presented) A method for treating graft rejection in organ transplantation or bone marrow transplantation in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

72. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to produce local analgesia or anesthesia in a warm-blooded animal in need thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

73. (Previously presented) A method for producing local analgesia or anesthesia in a warm-blooded animal in need thereof comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

74. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat heart failure in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

75. (Previously presented) A method for treating heart failure in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

76. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat hypotension in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

77. (Previously presented) A method for treating hypotension in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

78. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat Alzheimer's disease in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

79. (Previously presented) A method for treating Alzheimer's disease in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

80. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat dementia in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

81. (Previously presented) A method for treating dementia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

82. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to treat alopecia in a warm-blooded animal in need of the treatment, and a pharmaceutically acceptable carrier, diluent, or excipient.

83. (Previously presented) A method for treating alopecia in a warm-blooded animal comprising administering to a warm-blooded animal in need thereof a therapeutically effective amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

84. (Previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2 effective to enhance libido in a warm-blooded animal in need thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

85. (Previously presented) A method for enhancing libido in a warm-blooded animal in need thereof comprising administering to a warm-blooded animal in need thereof an enhancing amount of a compound according to claim 1 or a compound or mixture of compounds according to claim 2.

86. (Previously presented) A composition according to claim 1 or 3 or a compound or mixture of compounds according to claim 2, and a pharmaceutically acceptable carrier, excipient or diluent.

87. (Currently Amended) The ~~compound~~ composition according to claim 1 wherein R_1 and R_2 are taken together with the nitrogen atom to which they are directly attached in formula (I) to form a ring denoted by formula (II):



(II)

wherein the ring of formula (II) is formed from the nitrogen as shown as well as three to nine additional ring atoms independently selected from carbon, nitrogen, oxygen, and sulfur; where any two adjacent ring atoms may be joined together by single or double bonds, and where any one or more of the additional carbon ring atoms may be substituted with one or two substituents selected from hydrogen, hydroxy, C_1-C_3hydroxyalkyl, oxo, C_2-C_4acyl, C_1-C_3alkyl, C_2-C_4alkylcarboxy, C_1-C_3alkoxy, and C_1-C_{20}alkanoyloxy.

88. (Currently Amended) The ~~compound~~ composition according to claim 87 wherein the ring of formula II is a substituted or unsubstituted morpholinyl group or a substituted or unsubstituted ketopyrrolidinyl group, wherein in the substituted groups any one or more of the carbon ring atoms in the ring may be substituted with one or two substituents selected from hydrogen, hydroxy, C_1-C_3hydroxyalkyl, oxo, C_2-C_4acyl, C_1-C_3alkyl, C_2-C_4alkylcarboxy, C_1-C_3alkoxy, and C_1-C_{20}alkanoyloxy.

89. (Currently Amended) The ~~compound~~ composition according to claim 87 wherein the ring of formula II is a saturated ring.